Jun 13, 2024, 03:19
Amol Akhade: Everolimus vs Alpelisib vs Capivasertib
Amol Akhade, Consultant Medical Oncologist atSuyog Cancer Clinics, shared a post on X:
“Everolimus vs Alpelisib vs Capivasertib.
Even though PFS HR are similar for all 3 drugs, only capivasertib has phase III data in patients with cdk4- 6 exposure.
Toxicity profile for capivasertib is better as compared to alpelisib, especially for rash and hyperglycaemia.”
Source: Amol Akhade/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 22, 2024, 00:34
Oct 22, 2024, 00:24
Oct 21, 2024, 19:26
Oct 21, 2024, 19:21
Oct 21, 2024, 19:17
Oct 21, 2024, 19:14
Oct 21, 2024, 19:10